Michelle Detwiler, MD, PhD
LinkedIn Copy
Hey Michelle — similar-ish path (IB → growth equity), though on the London side. been thinking a lot about proprietary origination in pharma services lately. would be good to connect.
Hey Michelle, looks like we share a similar IB → PE background, though I was at CS & Greenhill in London not at GSK and General Atlantic like you. origination was always the same story for me — clear thesis, decent relationships, but no proprietary system of record tying anything together. every deal virtually sourced from scratch, nothing compounding over time. curious if that's still how most funds operate or if I'm behind the times? — Russ
Hey Michelle, looks like we share a similar background, though I was in London doing growth equity deals at Treis not building a life sciences platform out of General Atlantic like you. the pattern I keep seeing with most funds is weirdly consistent — strong thesis, solid network, but no proprietary system of record. the people, tools and ideas are never really connected. every deal virtually sourced from scratch, nothing compounds on itself. curious if that resonates or if you've built something different at Biospring? — Russ
hey Michelle — no worries if the timing's off. most funds I talk to have tried some version of building origination in-house — analyst pulling from Pitchbook, maybe using ChatGPT to help qualify, dumping it into a spreadsheet. each piece kind of works, but there's no system of record tying it together. the people, tools and ideas stay disconnected, so there's tonnes of wasted energy and everything ends up out of sync. been helping a few funds like Mentmore work through that. curious if you've run into the same thing at Biospring? — Russ
totally get it if origination infrastructure isn't top of mind right now — most funds have 10 things ahead of it on the priority list. the funds I've seen crack it early just tend to compound deal flow in a way that's hard to replicate later. if it ever moves up the list, I'm easy to find. — Russ
Email Copy
No email copy generated yet.
Prospect Research
## PROSPECT INFORMATION: Name: Michelle Detwiler, MD, PhD Title: Managing Partner Fund: Biospring Partners Background: Michelle Detwiler is a Co-Founder and Managing Partner at Biospring Partners, a New York-based healthcare growth equity firm specializing in life sciences and pharma services. She currently serves on several high-profile boards, including Cedar Health Research, Xavier University of Louisiana, and the Women’s Foundation of Boston. Her background is rooted in deep clinical and investment expertise, having previously launched General Atlantic’s first life sciences platform and co-founded the Longwood Fund. She also held the role of Senior Vice President at GlaxoSmithKline, leading global business development and M&A. Her academic credentials include a Bachelor of Medicine, Bachelor of Surgery (BM BCh), and a DPhil in Human Physiology from the University of Oxford. She is a recognized leader in the field, previously named one of Fortune’s 40 under 40 and a Young Global Leader by the World Economic Forum. Key Skills: Biotechnology, Life Sciences, Venture Capital, Clinical Development, and Pharmaceutical M&A. Recent Activity and Post Quotes: On February 20, 2026, she shared news regarding a portfolio company, stating: "Congratulations to Cedar Health Research and Texas Native Health:" On February 19, 2026, she invited her network to an event featuring a prominent advisor, posting: "Join us for a discussion w Sir John Bell Thurs 2/26 @930am:" On February 10, 2026, she highlighted a networking opportunity at a major industry event: "Join Abzena at DCAT: Let me know if you would like to set up a meeting with the Abzena leadership team. We would love to see you in NYC!" On January 7, 2026, she celebrated internal team growth at her firm: "Congratulations, Sidhart Nambiar, on your promotion! Very well deserved. We are so happy to happy to have you on our team:" On October 24, 2025, she shared details of a strategic commercial license: "Orion Pharma has announced that it has obtained an exclusive, focused commercial license to one of ABZENA PLC ’s monoclonal antibodies (#mAbs) targeting a cancer with high clinical unmet need." On December 29, 2025, she engaged with technical content regarding bioconjugation: "Great BioPharm International interview with Petra Dieterich, DPhil, MBA & Jeffrey C. Mocny, Ph.D. of Abzena: #biomanufacturing #complexbiologics #bioconjugation #ADCs #AOCs" Fund details: - Description: Biospring Partners is a life sciences focused growth equity firm. We invest in EBITDA+ innovative, technology-enabled B2B pharma services businesses in areas including outsourced complex biomanufacturing and clinical trials services. The main customers for Biospring's portfolio companies are top global pharma companies. - Website: https://www.biospring.com - Location: New York, New York, United States - Lead qualification: Research: - Query: =Biospring Partners Michelle Detwiler, MD, PhD recent investments fund thesis - Answer: Michelle Detwiler, MD, PhD, is a Managing Partner at Biospring Partners, focusing on healthcare private equity. She has significant experience in life sciences and technology investments. Biospring Partners invests in growth-stage life sciences technology companies.